Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Evogene, Ltd. (NASDAQ: EVGN).

Full DD Report for EVGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: EVGN)

Biomica Announces Participation in the Microbiome Invest Conference in London May 23, 2018
REHOVOT, Israel, May 14, 2018 (GLOBE NEWSWIRE) -- Biomica, a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform, announced today i...
Source: GlobeNewswire
Date: May, 14 2018 07:00
Evogene Financial Results for the First Quarter of 2018 Earnings Announcement Schedule
REHOVOT, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the first quarter of 2018 on Tuesday, May 29, 2018. ...
Source: GlobeNewswire
Date: May, 10 2018 07:00
Evogene and Marrone Bio Innovations Announce Phase Advancement in their Insect Control Collaboration
REHOVOT, Israel and DAVIS, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, and Marrone Bio Innovations Inc. (MBI), (NASDAQ:MBII), a leading global provider of bio-based pest ...
Source: GlobeNewswire
Date: May, 08 2018 07:00
Biomica, Evogene's Newly Established Subsidiary, Announces Therapeutic Areas of Focus
REHOVOT, Israel, May 01, 2018 (GLOBE NEWSWIRE) -- Biomica, a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform, announced today i...
Source: GlobeNewswire
Date: May, 01 2018 07:00
Evogene Files Annual Report for the Year Ended December 31, 2017
REHOVOT, Israel, April 01, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (CPB) platform, announced today that it has filed its a...
Source: GlobeNewswire
Date: April, 01 2018 07:00
Evogene's (EVGN) CEO, Ofer Haviv on Q4 2017 Results - Earnings Call Transcript
Evogene Ltd. (EVGN) Q4 2017 Earnings Conference Call February 28, 2018 9:00 am ET Executives Ofer Haviv - President, Chief Executive Officer Alex Taskar - Chief Financial Officer Analysts Tyler Etten - Piper Jaffray Presentation Operator Welcome to Evogene’s...
Source: SeekingAlpha
Date: February, 28 2018 12:00
Evogene misses by $0.03, beats on revenue
Evogene (NYSE: EVGN ): Q4 EPS of -$0.24 misses by $0.03 . More news on: Evogene Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: February, 28 2018 07:06
Evogene Reports Fourth Quarter and Full Year 2017 Financial Results
REHOVOT, Israel, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (CPB) platform, announced today its financial results fo...
Source: GlobeNewswire
Date: February, 28 2018 07:00
Evogene Announces Positive Results in its Novel Mode-of-Action Herbicide Program
REHOVOT, Israel, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN)) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (CPB) platform, announced today that its Ag-Chemical di...
Source: GlobeNewswire
Date: February, 27 2018 07:00
Evogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement Schedule
REHOVOT, Israel, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN)(TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today that it will release its financ...
Source: GlobeNewswire
Date: February, 12 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-212.952.873.002.871,289
2018-05-182.862.912.912.863,014
2018-05-172.922.90342.96322.908,286
2018-05-162.892.932.932.749,345
2018-05-152.902.882.902.8754,165

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-151613,3074.8685Cover
2018-08-142,8253,43582.2416Short
2018-08-0914,9660.0201Cover
2018-08-0711010.9901Cover
2018-08-068013,40123.5519Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EVGN.


About Evogene, Ltd. (NASDAQ: EVGN)

Logo for Evogene, Ltd. (NASDAQ: EVGN)

Not available

 

Contact Information

 

 

Current Management

  • Ofer Haviv / President, CEO

Current Share Structure

  • Market Cap: $110,887,031 - 05/11/2018
  • Issue and Outstanding: 36,596,380 - 12/15/2011

 


Recent Filings from (NASDAQ: EVGN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 28 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 20 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 12 2018

 

 


Daily Technical Chart for (NASDAQ: EVGN)

Daily Technical Chart for (NASDAQ: EVGN)


Stay tuned for daily updates and more on (NASDAQ: EVGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EVGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EVGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EVGN and does not buy, sell, or trade any shares of EVGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/